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S U M M A R Y
Background: With the abuse of antibiotics, the methicillin-resistant Staphylococcus aureus (MRSA) strain
became prevalent. Furthermore, Staphylococcus aureus with a character of vancomycin intermediate-
resistance (VISA) has been found globally since the ﬁrst report in Japan. The main objectives of this study
were to report a case of VISA isolated from a Chinese patient who had never undergone Vancomycin
treatment, and to determine its molecular character.
Methods: A total of 9 strains were recovered from a patient during the therapeutic process. Antimicrobial
susceptibility testing was performed to determine their antibiotic susceptibility patterns. To detect the
VISA strain’s molecular epidemiological features, growth and morphological characters, we used
multilocus sequence typing, autolysis assay and transmission electric microscope tests. Pulsed-ﬁeld gel
electrophoresis (PFGE) was performed to characterize the heterogeneities of all isolates.
Results: One isolate was found to exhibit vancomycin intermediated-resistant with MIC of 8 mg/ml. It
was ST239-T030-agr-1, had thickened cell wall, and displayed a slower growth rate and reduced
susceptibility to Triton X-100-induced autolysis than other strains. All 9 strains exhibited the same PFGE
pattern.
Conclusion: This is the ﬁrst report of VISA found in central China from a patient who had never received
vancomycin treatment.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Staphylococcus aureus remains a dominant cause of bacteraemia
worldwide due to its ability to adapt to different environments,
even to cope with antibiotic pressure.1 With the abuse of
antibiotics, the methicillin-resistant Staphylococcus aureus (MRSA)
strain became more prevalent. The prevalence of MRSA even
exceeded 70% of all S.aureus in Asia.2–4
MRSA infection is resistant to methicillin and related b-lactam
antibiotics. The therapy of MRSA infections began to shift to the use
of glycopeptide antibiotics in the 1980s, particularly Vancomycin.
Unfortunately, under the pressure of glycopeptide antibiotics,
Vancomycin intermediate-resistant Staphylococcus aureus (VISA)
emerged and was ﬁrstly reported in Japan in 1997.5 Since then
VISA has been isolated with increasing frequency from several
hospitals around the world.6–8 Mainland China also faced the same* Corresponding author.
E-mail address: tjszyong@163.com (Z. Sun).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).problem, as indicated by Sun W’s work.9 In most cases of
nosocomial VISA infection, Vancomycin application could be
found. In the present study, we report a ﬁrst VISA isolated from
a patient who received teicoplanin, Linezolid and other antibiotics,
but was never treated with Vancomycin.
As part of the study, we subjected all S.aureus strains from this
patient to antibiotic susceptibility testing, molecular typing, and
PFGE analysis. The VISA strain was further characterized by the
cell-wall thickening test and autolysis detection.
2. Materials and methods
2.1. Bacterial strains and patient
The VISA isolate was recovered from a large teaching hospital
with 3700 beds located in Central-Southern China (Tongji hospital,
Wuhan, China). The patient, a 51-year-old man, was admitted to
our hospital on Mar 18th, 2013 with a complaint of dysphagia for
one month, but no history of hospitalization. A presumptiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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examination. Then the patient underwent total gastrectomy,
subtotal esophageal resection via left chest and esophageal ostomy
in the left neck on Mar 21st. Cefoperazone/Tazobactam was
administered for 6 days as prophylaxis. However, MRSA isolates,
number 5135 (Mar 25th) and number 5247 (Mar 28th), were
recovered from the sputum specimens. On Mar 27th, the patient
started with Teicoplanin and Piperacillin/Tazobactam for 8 days.
The patient’s condition was improving. On Apr 4th, the patient
underwent the second surgery, colon interposition reconstruction
for oesophageal replacement via the left neck and digestive tract
reconstruction. Cefoperazone/Tazobactam and Teicoplanin were
administrated for 14 days. However, on Apr 6th and Apr 17th, MRSA
5493 and heterogeneous vancomycin-intermediate Staphylococ-
cus aureus (hVISA) 5916 were recovered from sputum specimens,
respectively. On Apr 17th, stoma ﬁstula was found with high WBC
of 11.3  109/L and neutrophils of 82.0%. On the second day, VISA
isolate 5944 was recovered from drainage of the stoma ﬁstula.
Then the antibiotics were changed to Meropenem and Linezolid for
9 days. At the same time, the patient was isolated in a private room
and a dedicated nurse was assigned to take care of him. In this
stage, a continuous drainage tube with negative pressure was set
to control the infection. Eight days later, the amount of drainage
decreased and the inﬂammation was relieved. The stoma ﬁstula
was constrained and enwrapped. The neck wound healed well.
Decreased WBC of 8.6  109/L and N% of 74.0% were achieved. On
Apr 27th, the regimen was changed back to Cefoperazone/
Tazobactam and Teicoplanin for the other days. On May 3rd, the
hospital infection control staff collected four specimens from this
patient, including nasal swabs (5964), secretions from the neck
wound (5966), anal swabs(5967) and sputum(5968). hVISA were
recovered from all these specimens. The patient abandoned
treatment and checked out on May 4th for economic reasons.
The summary of the patient’s course is presented in Figure 1. The
control strain Mu3 and Mu50 used in this study were a kind gift
from Professor Jingyun Li at the National Institutes for Food and
Drug Control.
Although the patient was not treated with Vancomycin during
the whole process in the present study, the use of Vancomycin
in this hospital is about 4.49 DDDs/100 admissions and the
prevalence of MRSA isolates was 69.5% in 2013. The percentage of
hVISA in MRSA isolates was considerably high in Central-Southern
China, up to 22.1%.10Figure 1. The patient’s clinical course. (The lower panel) The antibiotics used are depic
treatment with the antibiotics. (The top panel), All isolates are shown in the order in w2.2. Antimicrobial susceptibility testing
Identiﬁcation of S. aureus isolates was performed using
standard methods and the Vitek 2 compact automated system
(bioMe´rieux, Marcy-l’E´toile, France). Minimum inhibitory concen-
trations (MICs) of antibiotics were determined using the broth
microdilution method according to the Clinical and Laboratory
Standards Institute recommendations. Reference strain ATCC
29213 was used as control. E-test analysis of vancomycin and
teicoplanin were performed using E-test strips (bioMeriux,
Durham, NC) according to the manufacturer’s instructions.
2.3. Modiﬁed population analysis proﬁling/area under the curve (PAP/
AUC)
PAP/AUC was performed as previously described by Wootton
et al.11 Brieﬂy, following 24 h incubation in Tryptone Soya Broth
(Oxoid, Basingstoke, England), neat culture and dilutions of 103
(105 CFU/ml) and106 (102 CFU/ml) were plated onto Brain Heart
Infusion agar (Oxoid) plates containing 0.0, 0.5, 1.0, 2.0, 2.5, 4.0,
and 8.0 mg/L vancomycin. Colonies were counted after 48 h.
Control strains (Mu50, and Mu3) were included with each run.
The calculated CFU/mL values were plotted against vancomycin
concentration using Prism version 5.0 (GraphPad Software,
San Diego, CA, USA). The ratio of the AUC of the test isolate to
the AUC of Mu3 was calculated and interpreted as follows: for
VSSA, a ratio of <0.9; for hVISA, a ratio of 0.9 to 1.3; and for VISA,
a ratio of 1.3.
2.4. DNA isolation
All isolates were cultured on blood agar and incubated
overnight at 37 8C. Genomic DNA was extracted using Puregene
Yeast/Bact. Kit (Qiagen, Valencia, CA) according to the manufac-
turer’s protocol for Gram-positive bacteria. DNA samples were
stored at -20 8C until testing.
2.5. Molecular typing
Multiplex PCR was used to amplify the mecA gene and
determine the staphylococcal chromosome cassette mec (SCCmec)
type (I-V) of all MRSA isolates, according to the method published
by Milheirico et al.12 Multilocus sequence typing (MLST) wasted in rectangles. The number of days in each rectangle corresponds to the time of
hich they were recovered.
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keeping genes (arcC, aroE, glpF, gmk, pta, tpi, and yqiL) were
obtained from chromosomal DNA and were directly sequenced.
MLST allele names and sequence types were derived from the
MLST database (http://www.mlst.net/dbqry/saureus/htm). The
accessory gene regulator (agr) polymorphism was determined
by multiplex PCR using a previously described method.14 Spa
typing was performed as described by Harmsen et al,15 the spa
types with identical or similar repeat proﬁles were grouped into
clusters (http://www.ridom.de/spaserver).
2.6. Detection of the van genes
The vancomycin-resistant genes, including VanA, VanB, VanC1,
VanC2 and VanC3, were detected using a multiplex PCR as
previously described.16 The PCR cycle was as follows: 1 cycle of
5 min at 94 8C, then 35 cycles of 94 8C, 1 min, 58 8C, 1 min, and
72 8C 1 min; followed by a ﬁnal 10 min extension at 72 8C.
2.7. Autolysis assay
Triton X-100-stimulated autolysis in glycin buffer (pH8.0) was
measured as described previously.17 Cells were grown exponen-
tially to an OD600 of about 0.3. The cultures were then rapidly
chilled, and cells were washed twice with ice-cold distilled water
and resuspended to an OD600 of 1.2 in 50 mM glycine–0.01% Tris X-
100 buffer. Autolysis was measured every 30 min for 4 h in
absorbance at OD600. The percentage of the remaining optical
density at each time point was plotted.
2.8. Electron microscopic evaluation of cell wall thickness
Electron microscopy was performed as described previously
by Cui et al.18 Brieﬂy, mid-exponential-phase cells were
harvested, ﬁxed with 2.5% glutaraldehyde followed with
postﬁxation in 1% osmium tetroxide and then 1% aueous uranyl
acetate. Next, the samples were dehydrated and embedded in
Epon 812. The thin sections were stained with uranyl acetate
and lead citrate. Thirty cells of each strain with nearly equatorial
cut surfaces were measured for the evaluation of cell wall
thickness, and results were expressed as mean value standard
deviation (SD).Table 1
Comparison of antibiotic susceptibilities
Antimicrobial agents 5135 5247 5493 
Tigecycline 0.5 0.5 0.5 
Chloramphenicol 8 8 8 
Clindamycin 0.5 0.5 0.5 
Erythromycin 0.5 0.5 1 
fosfomycin 16 32 32 
Teicoplanin 2 2 2 
Linezolid 2 2 2 
Rifampin 64 64 64 
Teicoplanin 2 2 2 
TEC-Etest 3 2 2 
Vancomycin 1 1 1 
VAN-Etest 1 1 1 
Trimethoprim/sulfamethoxazole 1/19 1/19 1/19 
Tobramycin 256 256 256 
Gentamicin 256 256 256 
Levoﬂoxacin 256 256 256 
Penicillin 256 256 256 
Oxacillin 256 256 256 
Cefoxitin 256 256 256 
Cefazolin 256 256 256 
Cefuroxime 256 256 256 2.9. Pulsed-ﬁeld gel electrophoresis (PFGE)
PFGE was performed with CHEF MAPPER (Bio-Rad, Hercules,
CA) as described by Yoshida et al.19 The separated DNA fragments
digested with the enzyme SmaI were photographed after being
stained with ethidium bromide. Strains were considered identical
when they shared same number and sizes of fragments. The strains
varied with only two or three bands were considered closely
related.20
2.10. Statistical analysis
The statistical signiﬁcance of the data was evaluated by




All isolates were subjected to up to 19 antimicrobics, including
vancomycin (VAN) and teicoplanin (TEC). Table 1 shows that all
strains isolated from the same patient through the therapeutic
process displayed distinct antibiotic susceptibility patterns. All
isolates showed stable resistance to Penicillin, Oxacillin, Cefoxitin,
Cefazolin, Cefuroxime Tobramycin, Gentamicin, and Levoﬂoxacin,
while strain 5944 exhibited vancomycin intermediated-resistance
withMICof8ug/ml which meet the criteriaestablishedbythe Clinical
and Laboratory Standards Institute (CLSI) in 2013 (Figure 2A). The
antibiotic susceptibility pattern was further identiﬁed by PAP/AUC.
As shown in Figure 2B, the ratio of the AUC of the 5944 to the AUC of
Mu3 was >1.3. The ratio of clinical strains, 5916, 5965, 5966, 5967,
5968 was 0.90 to 1.3, was deﬁned as hVISA. The ratio of 5135, 5247,
5493 were <0.90, was deﬁned as VSSA.
3.2. Molecular characteristics and the presence of genes associated
with VISA
SCCmec typing revealed that all 9 isolates contained SCCmec
type III, and displayed mecA gene positive. MLST typing, Spa typing
and agr grouping test indicated that all 9 isolates belonged to5916 5944 5965 5966 5967 5968
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Figure 2. Population analysis proﬁle curves and vancomycin MIC by E-test. (A)
Strain 5944 was grown overnight in brain heart infusion medium and subjected to
vancomycin MIC by E-test. (B) Population analysis proﬁle of 9 isolates in this study
and 2 standard strains (VISA strain Mu50 and hVISA strain Mu3). The curves are
representative of at least 3 experiments with each strain.
Figure 4. Triton X-100 stimulated autolysis assay. Absorbance is represented as the
percentage of the absorbance at OD600 nm relative to that at time zero for each
sample. Strain 5944 exhibited decreased autolysis, the same as VISA control strain
Mu50. The test was repeated 3 times, and 1 representative was indicated.
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VanC was found in Strain 5944.
3.3. VISA growth rate and hemolytic activity
In addition to the test of antibiotic susceptibility, we got insight
into the change of morphological features of strain 5944. The size
of colonies formed on blood agar plates by strain 5944 (right panel)
was much smaller than that of 5135, a VSSA strain identiﬁed with
PAP/AUC (left panel), indicating a slower growth of the former
(Figure 3). Comparison of hemolytic zones induced by strain
5944 and 5135 showed the marginally signiﬁcant decrease of
hemolytic activity of VISA strain 5944 (Figure 3).
3.4. Susceptibility to Triton X-100 induced autolysis
Reduced susceptibility to Triton X-100-induced autolysis was
found in strain 5944 (Figure 4).Figure 3. Low growth rate and reduced hemolytic activity. strain 5135and strain
5944 were plated onto blood agar plates and incubated for 24 h at 37 8C. Strain
5135 had signiﬁcantly larger colonies than those of strain 5944 with invisible
hemolytic zone. The single colony of bacteria was marked with hollow arrow (5135)
or solid arrow (5944).3.5. Cell wall morphologies
A total of 4 Staphylococcus aureus strains, a standard VSSA strain
ATCC 25923, three clinical isolates 5135 (VSSA), 5916 (hVISA) and
5944(VISA) were subjected to morphometric study using trans-
mission electron microscopy. Figure 5A shows transmission
electron micrography of representative strains. As is evident in
Figure 5B, clinical VISA strain 5944 had signiﬁcantly thicker cell
walls than 5916, 5139 and the control strain ATCC 25923 (p<0.05).
3.6. PFGE patterns
All 9 clinical isolates were subjected to PFGE analysis. The same
DNA fragments were found in each electrophoresis channel (Fig. 6).
4. Discussion
In the present study, we report a case of VISA isolated from a 51-
year-old male patient in Tongji Hospital in China. It is the ﬁrst
report of VISA in Central-Southern China. Furthermore, it is
noteworthy that the patient was never treated with vancomycin.
The identiﬁed VISA strain, strain 5944 was subjected to SCCmec
typing and mecA detection, showing that strain 5944 was SCCmec
type III and mecA positive, a predominant strain in China, which is
linked with the previous report.9 SCCmec type III was a prevalent
MRSA clone in European countries, Australia, Thailand and so on,21
which is different from the conclusion from Katayama and
Buntaran’s studies that SCCmec II predominated in the Asian-
paciﬁc region.22
To further understand the molecular epidemiological features
of this VISA isolate, we sought to characterize it by MLST typing,
Spa typing and agr detection. Our data showed that strain 5944 in
this study belonged to MLST type ST239 and spa type t030, a
predominant strain in China, and even in the whole of Asia.23,24 Agr
detection demonstrated that 5944 belonged to agr type 1, one of
the most common MRSA clones in central-south China.10 However,
Moise-Broder’s work suggested that agr type 2 was more likely to
develop glycopeptide resistance than agr type 1 strains.25We think
this different characteristic might be due to the regional difference
because all samples in Moise’s study were recovered from the
United States and Japan. We did not harvest enough samples to
determine whether agr typing could be an independent predictor
of vancomycin treatment failure in patients with MRSA infection as
shown in the previous study.25 Our result of VISA genotyping was
the same as the previous report that was the ﬁrst report of VISA
from the Third Military Medical University, Chongqing, China.26
Figure 5. Transmission electron microscopy of representative strains. (A) Transmission electron microscopy of ATCC 25923, 5135, 5916 and 5944. Magniﬁcation, 25,000. (B)
Comparison of cell wall thickness between the strains ATCC 25923, 5135, 5916 and 5944. The data are expressed as the meanSD of 30 cells of each strain for determination and
were evaluated by the Student’s t test. P value less than 0.05 is considered statistically signiﬁcant. Ns = not signiﬁcant.
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staphylococcus aureus (GISA) include cell wall-thickening, re-
duced autolysis, decreased growth rate and hemolysis.27–29 In the
present study, both reduced autolysis and decreasing of growth
rate and hemolysis characterize this VISA isolate in Tongji hospital.
The signiﬁcant change of the cell wall of strain 5944 was found,
versus the standard strain Mu3. The previous study demonstrated
that cell wall thickening is responsible for both vancomycin
resistance and teicoplanin in staphylococcus aureus,26 which
might be attributed to same type of antibiotics both of them were
attributed to. However, the strain 5944 in this study remained
sensitive to teicoplanin.Figure 6. PFGE banding patterns of 9 clinical isolates. All isolates exhibited the exact
same PFGE pattern.To determine the mechanism of acquirement of reduced
vancomycin susceptibility of strain 5944, we also detected the
Van gene which was implicated in generation of Vancomycin
resistance.28,30 There are increasing documents showing that
S.aureus could acquire vancomycin resistance by transferring Van
genes including VanA, VanB and VanC,31–33 which was even
accomplished in the laboratory.34 But neither VanA, VanB nor VanC
was found in VISA isolate.
Since Vancomycin is regarded as one of the mainstays of
treatment for MRSA infection, the use of Vancomycin in this
hospital is common, about 4.49 DDDs/100 admissions, which led
to a high prevalence of hVISA in MRSA isolates.10 In the present
study, the patient with Esophageal cancer twice underwent
surgeries which might have induced poor physical health. Scott K
Fridkin et al’s study indicated that recurrent MRSA infection and
certain underlying illnesses might increase the risk of develop-
ment of VISA.35 It seemed that in this case, the serious underlying
illness and high chance of exposure to MRSA and hVISA
colonization might also contribute to VISA infection. But we
could not determine the reason behind it. This is the ﬁrst report of
VISA Isolated from a patient who never received Vancomycin
treatment.
By far, the overwhelming majority of S.aureus isolates still are
Vancomycin-susceptible, having an MIC in the range of 0.5-2ug/ml.
However, we must watch out for emergence of VISA or VRSA
among inpatients.
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